

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): October 20, 2023

**SIGYN THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**333-204486**  
(Commission  
File Number)

**47-2573116**  
(IRS Employer  
Identification No.)

2468 Historic Decatur Road  
Suite 140  
San Diego, California  
(Address of principal executive offices)

92106  
(Zip Code)

**Registrant's telephone number, including area code:** 619.368.2000

Prior address and phone number:

2468 Historic Decatur Road, Suite 140  
San Diego, CA  
(Address of principal executive offices)

92106  
(Zip Code)

619.353.0800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

From October 20, 2023, through October 25, 2023, the holders of \$1,322,200.00 of Original Issue Discount Senior Convertible Debentures elected to convert their debentures at an average contractual exercise price of \$0.18 per share in exchange for the issuance of 7,300,342 shares of the Company's Common Stock to the holders.

As a result of these issuances, the number of outstanding shares of the Company has increased from 44,231,402 to 51,531,744.

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SIGYN THERAPEUTICS, INC.**

Date: October 26, 2023

By: /s/ James A. Joyce

James A. Joyce, Chairman and CEO

---